Adipose-selective 11beta -HSD1 transgenic mice exhibited elevated intra-adipose and portal, but not systemic corticosterone levels, abdominal obesity, hyperglycaemia, insulin resistance, dyslipidaemia and hypertension
transgenic overexpression of 11beta -HSD1 in liver yielded an attenuated metabolic syndrome with mild insulin resistance, dyslipidaemia, hypertension and fatty liver, but not obesity or glucose intolerance
In women, it is much clearer that androgen excess is linked to the burden of CVD risk factors
insulin resistance is a consequence of androgen effects
Women with PCOS have a sustained exposure to high physiologic androgen levels. This condition is associated with endothelial dysfunction, obesity and metabolic abnormalities such as insulin resistance and dyslipidaemia
Further evidence of a link between high androgen levels and CVD or CVD risk factors is observed in women with polycystic ovary syndrome (PCOS)
For T treatment in aging women, the current data would suggest androgen excess has adverse effects on CVD risk factors, especially in women with diabetes
androgen use and abuse is increasing in our society, either for therapeutic or recreational reasons
For men, exogenous T treatment appears largely beneficial
I love these review articles that highlight the metabolic differences of hormones in women versus men. The medical community as a whole doesn't seem to get this at all. The marketing-based medical community doesn't either.